Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
88
Views
3
CrossRef citations to date
0
Altmetric
Case Report

A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma

Jieya Zou1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-9163-9058
ORCID Icon,
Xiaojuan Yang1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of China
,
Jiajun Duan1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of China
,
Ji Wang1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of China
,
Zhuangqing Yang1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of China
,
Dan Luo2 Department of Pathology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of China
,
Lihua Liu1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of China
,
Junyao Chen1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-8096-3936
ORCID Icon &
Jianyun Nie1 The Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, 650118, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 4599-4607 | Published online: 27 Aug 2021

Figures & data

Figure 1 The changes of Physical examination. (A) Physical examination on admission. (B) “EC” chemotherapy. (C) “PCb” chemotherapy. (D) the administration of anlotinib.

Figure 1 The changes of Physical examination. (A) Physical examination on admission. (B) “EC” chemotherapy. (C) “PCb” chemotherapy. (D) the administration of anlotinib.

Figure 2 The pathological examination of postoperative. (A) Some lamellar tumor cells, different sized cells, atypia, coarse chromatin, obvious nuclear division, and osteoclast-like cells. (B) Some tumor cells were tubular, while some were fusiform and atypical, with different sizes and in different stages of nuclear division. (C) Some cells are necrosis in the center of the tumor. (D) VIM (+) (4X10). (E) CD56 (+) (4X10). (F) ki-67 40% (4X10). (G) ER (-) (10X10). (H) PR (-) (10X10).

Figure 2 The pathological examination of postoperative. (A) Some lamellar tumor cells, different sized cells, atypia, coarse chromatin, obvious nuclear division, and osteoclast-like cells. (B) Some tumor cells were tubular, while some were fusiform and atypical, with different sizes and in different stages of nuclear division. (C) Some cells are necrosis in the center of the tumor. (D) VIM (+) (4X10). (E) CD56 (+) (4X10). (F) ki-67 40% (4X10). (G) ER (-) (10X10). (H) PR (-) (10X10).

Figure 3 Complete treatment process.

Figure 3 Complete treatment process.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.